Source:http://linkedlifedata.com/resource/pubmed/id/17204607
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
2007-1-5
|
pubmed:abstractText |
Graft engineering by CD34(+) selection of peripheral blood progenitor cells (PBPC) has been used in non-Hodgkin lymphoma (NHL) with the aim to reduce relapse related to tumor cells within the graft. From September 1995 to January 2000, 39 patients with newly diagnosed (n = 31) or relapsed (n = 8) NHL were treated in our institution with myeloablative therapy followed by CD34(+) selected autologous PBPC transplantation. Thirty-one patients were diagnosed with follicular lymphoma, and eight patients with mantle-cell lymphoma. All patients had advanced disease (26% of patients stage III and 74% stage IV, Ann Arbor classification). Induction therapy resulted in a complete remission in 17 patients and a partial remission in 22 patients. PBPC were mobilized after cytotoxic chemotherapy with granulocyte colony-stimulating factor support. CD34(+) selection was performed using immunomagnetic beads (Baxter Isolex 300SA or 300i Magnetic Cell Separation System). Most patients (85%) received total body irradiation and high-dose cyclophosphamide as myeloablative regimen. Twelve patients also received rituximab 375 mg/m(2) before radiation and before the start of the cyclophosphamide treatment. The mean CD34(+) cell number for transplantation was 6.5 x 10(6) CD34(+) cells/kg of body weight. Platelet recovery (>20,000/microl median on day 13) and leukocyte recovery (>1,000/microl median on day 12) were within expected range. The estimated median follow-up was 47 months. The probabilities of freedom from progression, overall survival, and event-free survival 4 years after transplantation were 96%, 90%, and 87%, respectively, for patients with follicular lymphoma and 42%, 63%, and 33%, respectively, for patients with mantle-cell lymphoma. Risk factors for relapse were age and extranodal manifestation of disease. The rate of lethal infections in the 12-month follow-up period was 8%. We conclude that CD34(+) selection of autologous transplants following myeloablative therapy is feasible and results in long-term remission in the majority of patients, but the procedure is probably related to a higher rate of lethal infections.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
1066-5099
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
25
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
228-35
|
pubmed:meshHeading |
pubmed-meshheading:17204607-Adult,
pubmed-meshheading:17204607-Antigens, CD34,
pubmed-meshheading:17204607-Cell Survival,
pubmed-meshheading:17204607-Female,
pubmed-meshheading:17204607-Follow-Up Studies,
pubmed-meshheading:17204607-Hematopoietic Stem Cell Mobilization,
pubmed-meshheading:17204607-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:17204607-Hematopoietic Stem Cells,
pubmed-meshheading:17204607-Humans,
pubmed-meshheading:17204607-Lymphoma, Non-Hodgkin,
pubmed-meshheading:17204607-Male,
pubmed-meshheading:17204607-Middle Aged,
pubmed-meshheading:17204607-Retrospective Studies,
pubmed-meshheading:17204607-Transplantation, Autologous
|
pubmed:year |
2007
|
pubmed:articleTitle |
Long-term follow-up of patients with non-Hodgkin lymphoma following myeloablative therapy and autologous transplantation of CD34+-selected peripheral blood progenitor cells.
|
pubmed:affiliation |
Department of Hematology and Oncology, University Hospital Heidelberg, Heidelberg, Germany. mathias.witzens-harig@med.uni-heidelberg.de
|
pubmed:publicationType |
Journal Article
|